Not logged in...
About USC Norris
FAQ - Trials
Contact Us - Trials
Support USC Norris
» Contact Us
If you are a patient, please contact
Keck Medical Center of USC
A Phase I, Dose Escalation, Multi-Center Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects with Intermediate-2 or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML).
Closed to Accrual with Ongoing Follow-up
Defintions of terms and FAQ about clinical trials.
Casey O Connell, M.D.
Other Trial Staff:
Ibrahim Syed, D.M.
to see study documents.
You may participate in this study if:
Confirmed diagnosis of IPSS intermediate-2 or high-risk MDS or AML: a) In the Dose Escalation Segment, subjects who are refractory, relapsed, or unresponsive to standard treatment will be the only ones allowed. b) In the Dose Expansion Segment, treatment-naïve MDS subjects are allowed, and treatment-naïve AML subjects who are at least 65 years of age will be allowed if they also have at least one of the following criteria:  AML secondary to MDS, chemotherapy, or radiation therapy,  poor cytogenetics defined as monosomies or partial deletions of chromosome 5 or 7 (del(5q), del(7q), -5, -7), abnormalities involving the long arm of chromosome 3 (q21;q26), t(6;9) (p23;q34), t(9;22) (q34;q11.2), or abnormalities including the long arm of chromosome 11 (11q23), or subjects with 3 or more unrelated cytogenetic abnormalities of any kind, or  pre-existing clinically significant dysfunction of the heart (LVEF <50%) or lung (DLCO or FEV1 <50% of expected) which is unrelated to the leukemia.
Men or women, 18 years of age or older
ECOG performance status of 0 to 2
Total bilirubin < / = 2 x uln; SGOT and SGPT < / = 2.5 x uln
Creatinine < / = 1.5 x uln
For subjects with prior allogeneic stem cell transplant, no evidence of active graft-versus host disease (GVHD) and must be = / > 2 weeks off immunosuppressive therapy
Willing to comply with the protocol
Signed an approved study-specific informed consent and HIPAA
You may not participate in this study if:
Major surgery within 4 weeks of first dose of SGI-110
Chemotherapy within 2 weeks of first dose of SGI-110 (minimum of 6 weeks for nitrosoureas and 8 weeks for BMT with the exception of hydroxyurea which will be allowed for 7 days after first dose of SGI-110.
Refractory to prior decitabine treatment
Subjects with inaspirable bone marrow
Subjects with acute promyelocytic leukemia (M3 classification)
Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in-situ cervical cancer, or other cancer from which the subject has been disease-free for at least 5 years
Life-threatening illness other than MDS or AML, uncontrolled medical condition or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, or put the study outcomes at risk
Uncontrolled or symptomatic arrhythmias or any NYHA Class 3 or 4 cardiac disease
Symptomatic CNS metastases or lesions for which treatment is required
Prior radiation therapy for extramedullary disease within 2 weeks of randomization
= / > Gr 2 toxicity (other than alopecia) continuing from prior anti-cancer therapy including radiation
Known history of HIV or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV)
Prior treatment with any investigational drug within 4 weeks of randomization
Being treated with systemic corticosteroids (other than for pre-medications or intermittent doses such as those used for allergic reactions and control of asthma)
Uncontrolled active systemic infections
Superimposed autoimmune hemolytic anemia or thrombocytopenia
Hypersensitivity to decitabine, SGI-110, or SGI-110 excipients
Uncontrolled CHF, CAD, COPD, or LVEF of < / = 50%, except for treatment-naïve elderly AML subjects
Pregnant or breastfeeding women. Women of childbearing potential must have a negative pregnancy test at screening and must be practicing two acceptable methods of birth control. Acceptable methods of birth control include IUD; oral, dermal (“patch”), implanted or injected contraceptives; tubal ligation; and barrier methods with spermicide. Women must also be willing to use 2 acceptable methods of contraception for 60 days after the last dose of study drug. Women of non-childbearing potential are those having hysterectomy; bilateral oophorectomy; or menopause defined as no menses for 1 year and FSH levels in the menopausal range. Men should not father a child while receiving SGI-110 treatment and for 2 months following completion of treatment. Men with female partners of childbearing potential should use effective contraception during this time.
For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or
To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.